SEARCH

SEARCH BY CITATION

Keywords:

  • Adjuvant therapy;
  • gynaecological cancer;
  • ovarian cancer;
  • surgery

The recommendation in 1999, by the National Health Service Executive (NHSE) that the management of gynaecological cancer be centralised, led to a reorganisation of services for women with gynaecological malignancies. Debate has continued about the feasibility and benefits of ovarian cancer centralisation particularly because its insidious presentation can make it difficult to identify women with ovarian cancer before surgery. Despite this, there is clear evidence that centralisation is advantageous to women in terms of quality of life, morbidity and survival.